AstraZenecaAZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Employees: 89,900
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 151 | Existing positions closed: 82
64% more funds holding in top 10
Funds holding in top 10: 11 [Q1] → 18 (+7) [Q2]
53% more repeat investments, than reductions
Existing positions increased: 500 | Existing positions reduced: 327
49% more call options, than puts
Call options by funds: $500M | Put options by funds: $336M
14% more capital invested
Capital invested by funds: $34.1B [Q1] → $38.9B (+$4.71B) [Q2]
6% more funds holding
Funds holding: 1,122 [Q1] → 1,191 (+69) [Q2]
0.37% less ownership
Funds ownership: 32.49% [Q1] → 32.12% (-0.37%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
TD Cowen Steve Scala 0% 1-year accuracy 0 / 3 met price target | 23%upside $95 | Buy Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 33 articles about AZN published over the past 30 days
